Structural epitope profiling identifies antibodies associated with critical COVID-19 and long COVID
Kearns, P. K. A.; Badonyi, M.; Lee, K.; Fleming, O.; Gerasimivicous, L.; Benton, S.; Guy, J.; Neilson, S.; Wise, H.; Jenks, S.; Templeton, K.; Dold, C.; Lambe, T.; Mentzer, A. J.; Knight, J.; Pollard, A.; COMBAT, ; Menon, M.; Hussell, T.; CIRCO, ; McWhirter, L.; Carson, A.; Fragkoudis, R.; Rosser, S.; Cavanagh, D.; Marsh, J. A.; Kleinjan, D. A.; Gilbert, N.
Show abstract
Even within a single protein, antibody binding can have beneficial, neutral, or harmful effects during the response to infection. Resolving a polyclonal antibody repertoire across a pathogens proteome to specific epitopes may therefore explain much of the heterogeneity in susceptibility to infectious disease. However, the three-dimensional nature of antibody-epitope interactions makes the discovery of non-obvious targets challenging. We implemented a novel computational method and synthetic biology pipeline for identifying epitopes that are functionally important in the SARS-CoV-2 proteome and identified an IgM-dominant response to an exposed Membrane protein epitope which to our knowledge is the strongest correlate of severe disease identified to date (adjusted OR 72.14, 95% CI: 9.71 - 1300.15), stronger even than the exponential association of severe disease with age. We also identify persistence (> 2 years) of this IgM response in individuals with longCOVID, and a correlation with fatigue and depression symptom burden. The repetitive arrangement of this epitope and the pattern of isotype class switching is consistent with this being a previously unrecognized T independent antigen. These findings point to a coronavirus host-pathogen interaction characteristic of severe virus driven immune pathology. This epitope is a promising vaccine and therapeutic target as it is highly conserved through SARS-CoV-2 variant evolution in humans to date and in related coronaviruses (e.g. SARS-CoV), showing far less evolutionary plasticity than targets on the Spike protein. This provides a promising biomarker for longCOVID and a target to complement Spike-directed vaccination which could broaden humoral protection from severe or persistent disease or novel coronavirus spillovers. One-Sentence SummaryUsing a novel protein-structure-based B cell epitope discovery method with a wide range of possible applications, we have identified a simple to measure host-pathogen antibody signature associated with severe COVID-19 and longCOVID and suggest the viral Membrane protein contains an epitope that acts as a T independent antigen during infection triggering extrafollicular B cell activation.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.